TW223059B
(de)
|
1991-07-23 |
1994-05-01 |
Schering Corp |
|
LT3300B
(en)
|
1992-12-23 |
1995-06-26 |
Schering Corp |
Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
|
LT3595B
(en)
|
1993-01-21 |
1995-12-27 |
Schering Corp |
Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
|
EP0707567B1
(de)
|
1993-07-09 |
2001-09-12 |
Schering Corporation |
Verfahren zur herstellung von azetidinonen
|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5627176A
(en)
|
1994-03-25 |
1997-05-06 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
AU2943095A
(en)
|
1994-06-20 |
1996-01-15 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
CA2200436A1
(en)
|
1994-09-20 |
1996-04-04 |
Pfizer Inc. |
Combination therapy for hypercholesterolemia
|
US5633246A
(en)
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
EP0877750B1
(de)
|
1995-10-31 |
2002-06-19 |
Schering Corporation |
Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
|
WO1997016424A1
(en)
|
1995-11-02 |
1997-05-09 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
|
US5739321A
(en)
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
US5886171A
(en)
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US5756470A
(en)
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
US5919672A
(en)
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
CA2353981C
(en)
|
1998-12-07 |
2005-04-26 |
Schering Corporation |
Process for the synthesis of azetidinones
|
IL143944A0
(en)
|
1998-12-23 |
2002-04-21 |
Searle Llc |
Combinations for cardiovascular indications
|
CN1249250C
(zh)
|
1999-04-05 |
2006-04-05 |
先灵公司 |
用于制备1-(4-氟苯基)-3(R)-[3(S)-羟基-3-(4-氟苯基)丙基]-4(S)-(4-羟苯基)-2-β丙内酰胺的立体选择性微生物还原反应
|
US6593078B1
(en)
|
1999-04-16 |
2003-07-15 |
Schering Corporation |
Use of azetidinone compounds
|
DE10042447A1
(de)
|
2000-08-29 |
2002-03-28 |
Aventis Pharma Gmbh |
Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
|
SI1593670T1
(sl)
|
2000-12-20 |
2007-12-31 |
Schering Corp |
S hidroksi substituirani 2-azetidinoni, uporabni kot sredstva za zniĹľevanje holesterola
|
IL156552A0
(en)
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
JP2004516289A
(ja)
*
|
2000-12-21 |
2004-06-03 |
アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
ジフェニルアゼチジノン誘導体、その調製方法、その化合物を含む薬剤およびその使用
|
RS50864B
(sr)
|
2000-12-21 |
2010-08-31 |
Sanofi-Aventis Deutschland Gmbh. |
Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
|
CN100522159C
(zh)
|
2001-01-26 |
2009-08-05 |
先灵公司 |
取代的氮杂环丁烷酮化合物在制备治疗谷甾醇血症的药物中的应用
|
HUP0303915A3
(en)
|
2001-01-26 |
2012-12-28 |
Merck Sharp & Dohme |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
MXPA03006631A
(es)
|
2001-01-26 |
2004-03-18 |
Schering Corp |
Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
|
IL156488A0
(en)
|
2001-01-26 |
2004-01-04 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
EP1671650A1
(de)
|
2001-01-26 |
2006-06-21 |
Schering Corporation |
Kombinationen von einem Hemmer der Sterol-Absorption und Nicotinsäure zur Behandlung von kardiovaskulären Indikationen
|
KR20040025889A
(ko)
|
2001-01-26 |
2004-03-26 |
쉐링 코포레이션 |
혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와심혈관성 제제의 조합물
|
TWI291957B
(en)
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
EP1389114A2
(de)
|
2001-03-08 |
2004-02-18 |
Merck & Co., Inc. |
Kombinationstherapie aus einem antihypertensiven mittel und einem cholesterin-absorptionshemmer
|
KR100590342B1
(ko)
|
2001-03-28 |
2006-06-15 |
쉐링 코포레이션 |
아제티딘온 중간체 화합물의 에난티오-선택적 합성법
|
AR038956A1
(es)
|
2001-05-25 |
2005-02-02 |
Schering Corp |
Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto
|
WO2003026643A2
(en)
|
2001-09-21 |
2003-04-03 |
Schering Corporation |
Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
|
CA2460344A1
(en)
|
2001-09-21 |
2003-04-03 |
Schering Corporation |
Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
AU2003225027A1
(en)
|
2002-04-16 |
2003-11-03 |
Merck And Co., Inc. |
Combination therapy using a ppar alpha/gamma agonist
|
DE10227506A1
(de)
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
DE10227508A1
(de)
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
DE10227507A1
(de)
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
US6761509B2
(en)
|
2002-07-26 |
2004-07-13 |
Jan Erik Jansson |
Concrete module for retaining wall and improved retaining wall
|
AR040588A1
(es)
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
EP1545479B1
(de)
|
2002-07-30 |
2010-10-27 |
Karykion Inc. |
Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
|
US6960047B2
(en)
|
2002-08-02 |
2005-11-01 |
Innovative Technology Application, Inc. |
Protection barrier apparatus
|
CN1330667C
(zh)
|
2002-08-06 |
2007-08-08 |
塞诺菲-安万特德国有限公司 |
分离肠胆固醇结合蛋白的方法
|
WO2004043457A1
(en)
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
CA2517571C
(en)
|
2003-03-07 |
2011-07-05 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
EP1626954A2
(de)
|
2003-05-05 |
2006-02-22 |
Ranbaxy Laboratories, Ltd. |
Verfahren zur herstellung von trans-isomeren von diphenylazetidinonderivativen
|
US20040259179A1
(en)
|
2003-05-30 |
2004-12-23 |
Gerd Assmann |
Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
|
US7002008B2
(en)
|
2003-06-16 |
2006-02-21 |
Bomi Patel Framroze |
Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one
|
JP2005015434A
(ja)
|
2003-06-27 |
2005-01-20 |
Kotobuki Seiyaku Kk |
血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
|
WO2005021495A2
(en)
|
2003-08-25 |
2005-03-10 |
Microbia Inc. |
Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
|
EP1522541A1
(de)
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Neue hypocholesterolemische Verbindungen
|
US20070135357A1
(en)
|
2003-10-30 |
2007-06-14 |
Sings Heather L |
Anti-hypercholesterolemic compounds
|
WO2005042692A2
(en)
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
|
EP1680189A2
(de)
|
2003-11-05 |
2006-07-19 |
Schering Corporation |
Kombinationen von lipidmodulierenden mitteln mit substituierten azetidinonen zur behandlung von vaskularen erkrankungen
|
EA010026B1
(ru)
|
2003-11-10 |
2008-06-30 |
Майкробиа, Инк. |
4-биарилил-1-фенилазетидин-2-оны
|
EP1687287A1
(de)
|
2003-11-24 |
2006-08-09 |
Hetero Drugs Limited |
Neues verfahren für ein ezetimib-zwischenprodukt
|
EP1695706A1
(de)
|
2003-12-17 |
2006-08-30 |
Dainippon Sumitomo Pharma Co., Ltd. |
Medizinische zusammensetzungen und kombinationen
|
CN100471835C
(zh)
|
2003-12-23 |
2009-03-25 |
默克公司 |
抗高胆固醇血症化合物
|
CA2550215A1
(en)
|
2003-12-23 |
2005-07-07 |
Astrazeneca Ab |
Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
|
US20050171080A1
(en)
|
2003-12-23 |
2005-08-04 |
Dr. Reddy's Laboratories, Inc. |
Polymorphs of ezetimibe and process for preparation thereof
|
GB0329778D0
(en)
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
WO2005066120A2
(en)
|
2003-12-30 |
2005-07-21 |
Ranbaxy Laboratories Limited |
Process for asymmetric synthesis of hydroxy-alkyl substituted azetidinone derivatives
|
CA2553769C
(en)
|
2004-01-16 |
2011-01-04 |
Merck & Co., Inc. |
Npc1l1 (npc3) and methods of identifying ligands thereof
|
ZA200609584B
(en)
|
2004-01-20 |
2008-06-25 |
Panacea Biotec Ltd |
Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
|
PT1756049E
(pt)
|
2004-05-21 |
2007-12-17 |
Sanofi Aventis Deutschland |
Processo para a preparação de derivados de 1,4-difenilazetidinona
|
DE102004025072A1
(de)
|
2004-05-21 |
2005-12-15 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
|
WO2006017257A2
(en)
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Azetidinone derivatives
|
US20060046996A1
(en)
|
2004-08-31 |
2006-03-02 |
Kowa Co., Ltd. |
Method for treating hyperlipidemia
|
MX2007003732A
(es)
|
2004-09-29 |
2007-04-23 |
Schering Corp |
Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
|
US20060160785A1
(en)
|
2004-12-03 |
2006-07-20 |
Judith Aronhime |
Ezetimibe polymorphs
|
CA2591564A1
(en)
|
2004-12-20 |
2006-06-29 |
Schering Corporation |
Process for the synthesis of azetidinones
|
IL166149A0
(en)
|
2005-01-05 |
2006-01-15 |
Hadasit Med Res Service |
Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity
|
EP1851197A2
(de)
|
2005-02-09 |
2007-11-07 |
Microbia, Inc. |
Phenylazetidinon-derivate
|
US20090186834A1
(en)
|
2005-03-24 |
2009-07-23 |
Microbia, Inc. |
Diphenylheterocycle cholesterol absorption inhibitors
|
WO2006107936A1
(en)
|
2005-04-04 |
2006-10-12 |
Pontificia Universidad Catolica De Chile |
The use of ezetimibe in the prevention and treatment of cholesterol gallstones
|
WO2006116499A1
(en)
|
2005-04-26 |
2006-11-02 |
Microbia, Inc. |
4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
|
EP1877373A2
(de)
|
2005-05-05 |
2008-01-16 |
Microbia, Inc. |
Biphenylazetidinonverbindungen als inhibitoren der cholesterinabsorption
|
WO2006122186A2
(en)
|
2005-05-10 |
2006-11-16 |
Microbia, Inc. |
1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
|
CA2608075A1
(en)
|
2005-05-11 |
2006-11-16 |
Microbia, Inc. |
Processes for production of phenolic 4-biphenylylazetidin-2-ones
|
EP1885694A2
(de)
|
2005-05-13 |
2008-02-13 |
Microbia, Inc. |
4-biarylyl-1-phenylazetidin-2-one
|
EP1896135A2
(de)
|
2005-05-25 |
2008-03-12 |
Microbia, Inc. |
Verfahren zur herstellung von 4-(biphenylyl)azetidin-2-on-phosphonsäuren
|
EP1893222A4
(de)
|
2005-06-15 |
2010-07-07 |
Merck Sharp & Dohme |
Anti-hypercholesterinämische verbindungen
|
WO2006134604A1
(en)
|
2005-06-15 |
2006-12-21 |
Hetero Drugs Limited |
Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
|
UY29607A1
(es)
|
2005-06-20 |
2007-01-31 |
Astrazeneca Ab |
Compuestos quimicos
|
AR056866A1
(es)
|
2005-06-22 |
2007-10-31 |
Astrazeneca Ab |
Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
|
AR054482A1
(es)
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
MY148538A
(en)
|
2005-06-22 |
2013-04-30 |
Astrazeneca Ab |
Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
|
AR057380A1
(es)
|
2005-06-22 |
2007-11-28 |
Astrazeneca Ab |
Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
|
AR057383A1
(es)
|
2005-06-22 |
2007-12-05 |
Astrazeneca Ab |
Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
|
SA06270191B1
(ar)
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
CA2613239A1
(en)
|
2005-06-22 |
2006-12-28 |
Manne Satyanarayana Reddy |
Improved process for the preparation of ezetimibe
|
EP1741427A1
(de)
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe
|
WO2007008541A2
(en)
|
2005-07-08 |
2007-01-18 |
Kalypsys, Inc. |
Cellular cholesterol absorption modifiers
|
WO2007008529A2
(en)
|
2005-07-08 |
2007-01-18 |
Kalypsys, Inc |
Celullar cholesterol absorption modifiers
|
WO2007016643A2
(en)
|
2005-08-01 |
2007-02-08 |
Mount Sinai School Of Medicine Of New York University |
A method for extending longevity using npc1l1 antagonists
|
EP1912937A1
(de)
|
2005-08-01 |
2008-04-23 |
Warner-Lambert Company LLC |
Neue substituierte azetidinone
|
WO2007017705A1
(en)
|
2005-08-09 |
2007-02-15 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of azetidinones
|
US20070049748A1
(en)
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
JP2008517951A
(ja)
|
2005-09-08 |
2008-05-29 |
テバ ファーマシューティカル インダストリーズ リミティド |
(3r,4s)−4−((4−ベンジルオキシ)フェニル)−1−(4−フルオロフェニル)−3−((s)−3−(4−フルオロフェニル)−3−ヒドロキシプロピル)−2−アゼチジノン、すなわちエゼチミベの合成のための中間体の調製方法
|
TW200806623A
(en)
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
TW200803868A
(en)
|
2005-11-15 |
2008-01-16 |
Takeda Pharmaceutical |
Novel method for treating hyperlipidemia
|
DE102005055726A1
(de)
|
2005-11-23 |
2007-08-30 |
Sanofi-Aventis Deutschland Gmbh |
Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
US7498431B2
(en)
|
2005-12-01 |
2009-03-03 |
Bomi Patel Framroze |
Process for the preparation of chiral azetidinones
|
HU0501164D0
(en)
|
2005-12-20 |
2006-02-28 |
Richter Gedeon Vegyeszet |
New industrial process for the production of ezetimibe
|
EP1962835A2
(de)
|
2005-12-21 |
2008-09-03 |
Schering Corporation |
Behandlung nicht alkoholinduzierter fettleber mittels cholesterinsenkenden mitteln und/oder h3-rezeptor-antagonisten oder -inversagonisten
|
TW200811098A
(en)
*
|
2006-04-27 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
EP2066668A1
(de)
*
|
2006-09-15 |
2009-06-10 |
Schering Corporation |
Spirozyklische azetidinon-derivate zur behandlung von fettstoffwechselkrankheiten, schmerzen, diabetes und anderen erkrankungen
|
WO2008108486A1
(ja)
*
|
2007-03-06 |
2008-09-12 |
Teijin Pharma Limited |
1-ビアリールアゼチジノン誘導体
|
US7624915B2
(en)
*
|
2008-02-04 |
2009-12-01 |
Riverwest Engineering & Design, Inc. |
Recycling center
|